X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET
Company Participants
Daniel Ferry - IR, LifeSci Advisors
Paula Ragan - CEO
Christophe Arbet-Engels - Chief Medical Officer
Mark Baldry - CCO
Conference Call Participants
Kristen Kluska - Cantor
Edward Tenthoff - Piper Sandler
Swayampakula Ramakanth - H.C. Wainwright
Stephen Willey - Stifel
David Bautz - Zacks
Operator
Greetings, and welcome to the X4 Pharmaceuticals Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded.
It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.
Daniel Ferry
Thank you, operator, and good morning, everyone. Thank you for joining us today for the special earnings call during which X4 will focus on providing a business update and, importantly, data and results from its now completed Phase II study of mavorixafor in chronic neutropenia.
As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development and commercialization plans, as well as research activities and financial projections. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
Description of these risks can be found in X4's most recent filings with the SEC, including this year's Form 10-K, which was filed on March 21, 2024, and in the company's Form 10-Q for the third quarter, which is expected to be filed shortly.
Presenting on today's call will be Dr. Paula Ragan, X4's President and CEO; and the company's Chief Medical Officer, Dr. Christophe Arbet-Engels.
I'll now turn it over to Paula Ragan to run through today's agenda. Paula?
Paula Ragan
Thank you, Dan, and thank you all for joining us. Today, we will provide an update on our operational achievements, including activities supporting the launch of XOLREMDI in the U.S. and the substantial progress to date with our ongoing Phase III clinical trial of mavorixafor in people with chronic neutropenia or CN.
In addition, we're excited to present the positive data from our recently completed Phase II study of mavorixafor in CN. These results include the final mavorixafor monotherapy data, which remains very encouraging and consistent with the data we presented in June from the interim Phase II analysis.
We will also be presenting new data from the study. Results showing that most of the participants who were treated with mavorixafor and G-CSF ended up having their G-CSF dose adjusted downward during the study, while the mean neutrophil count for this group remained in the normal range. These data provide a first glimpse into how mavorixafor could be used in the real world if ultimately approved in CN.